{"id":84,"date":"2019-10-14T02:23:28","date_gmt":"2019-10-14T06:23:28","guid":{"rendered":"http:\/\/www.creativebiomart.org\/alzheimacy\/?page_id=84"},"modified":"2020-09-06T23:52:39","modified_gmt":"2020-09-07T03:52:39","slug":"a%ce%b2-amyloid-pathway-as-drug-targets","status":"publish","type":"page","link":"https:\/\/www.creativebiomart.net\/alzheimacy\/target\/abeta-amyloid-pathway-as-drug-targets\/","title":{"rendered":"A\u03b2 Amyloid Pathway as Drug Targets"},"content":{"rendered":"

The amyloid hypothesis is an important theory to explain the cause of Alzheimer\u2019s disease\u00a0(AD) currently, which is supported by the most research evidence, and the most powerful evidence is the study of patients with early-onset FAD. This hypothesis holds that the equilibrium between the production and clearance of amyloid \u03b2 (A\u03b2) leads to the A\u03b2 accumulation in the brain parenchyma, which triggers a series of cascades and eventually leads to the damage and death of brain neurons, the fundamental cause of the decline of memory and cognition in patients with AD.<\/p>\n


\nFigure 1.\u00a0The amyloid cascade hypothesis<\/p>\n

Based on this theory, different therapies targeting A\u03b2\u00a0have been developed. A general view is that any strategy to reduce A\u03b2 levels in the brain by inhibiting A\u03b2 production\/aggregation or by increasing its clearance would be beneficial in preventing the development of AD. Review of the latest AD drug development pipeline shows that A\u03b2 remains the primary therapeutic target for AD.<\/p>\n


\nFigure 2.\u00a0The proportion of AD agents targeting\u00a0A\u03b2 amyloid pathway in clinical trials in 2018<\/p>\n

Strategies Targeting A\u03b2 Amyloid Pathway <\/strong><\/p>\n